US 12,352,758 B2
Quantitative biomarkers of EHV-1 susceptibility and protection
Bettina Wagner, Ithaca, NY (US)
Assigned to CORNELL UNIVERSITY, Ithaca, NY (US)
Appl. No. 16/975,589
Filed by CORNELL UNIVERSITY, Ithaca, NY (US)
PCT Filed Feb. 26, 2019, PCT No. PCT/US2019/019489
§ 371(c)(1), (2) Date Aug. 25, 2020,
PCT Pub. No. WO2019/165397, PCT Pub. Date Aug. 29, 2019.
Claims priority of provisional application 62/643,801, filed on Mar. 16, 2018.
Claims priority of provisional application 62/635,232, filed on Feb. 26, 2018.
Prior Publication US 2020/0408777 A1, Dec. 31, 2020
Int. Cl. G01N 33/68 (2006.01)
CPC G01N 33/6854 (2013.01) [G01N 33/6866 (2013.01); G01N 33/6893 (2013.01); G01N 2333/03 (2013.01); G01N 2333/521 (2013.01); G01N 2333/56 (2013.01); G01N 2333/70596 (2013.01); G01N 2800/26 (2013.01)] 15 Claims
 
1. A method comprising:
(a) providing an intranasal sample from a horse in a herd of horses;
(b) detecting in said sample equine herpes virus type 1 (EHV-1) specific immunoglobulin G1 (IgG1) and EHV-1 specific immunoglobulin G4/7 (IgG4/7), wherein the EHV-1 specific IgG1 and the EHV-1 specific IgG4/7 are both directed against a glycoprotein C (gC) of EHV-1, and wherein the detection of the EHV-1 specific IgG4/7 and the EHV-1 specific IgG1 is achieved by a multiplex assay based on use of a gC/IL-4 fusion protein;
(c) determining whether the horse is susceptible or immune to EHV-1 infection, or is undergoing an infection,
wherein the horse is susceptible to EHV-1 infection or is at an early stage of EHV-1 infection if the levels of the EHV-1 specific IgG1 and the EHV-1 specific IgG4/7 are both below respective threshold levels;
wherein the horse is at a late stage of EHV-1 infection if the levels of the EHV-1 specific IgG1 and the EHV-1 specific IgG4/7 are both above respective threshold levels; and
wherein the horse is immune to EHV-1 infection, if the level of the EHV-1 specific IgG1 is below a respective threshold level, the level of EHV-1 specific IgG4/7 is above a respective threshold level, and the ratio of the level of the EHV-1 specific IgG4/7 versus the level of the EHV-1 specific IgG1 is more than 10; and
(d) quarantining the horse away from other horses in the herd during an EHV-1 outbreak if the horse is susceptible to EHV-1 infection or at an early or late stage of EHV-1 infection, wherein the horse is quarantined for at least 14 days if the horse is susceptible to EHV-1 infection or is at an early stage infection, and the horse is quarantined for not more than 14 days if the horse is at a late stage of EHV-1 infection; and
not quarantining the horse if the horse is immune to EHV-1 infection.